Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects

被引:18
作者
Geus, WP
Mathôt, RAA
Mulder, PGH
Lamers, CBHW
机构
[1] Leyenburg Hosp, Dept Intens Care, NL-2504 LN The Hague, Netherlands
[2] Leyenburg Hosp, Dept Gastroenterol, NL-2504 LN The Hague, Netherlands
[3] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[4] Erasmus Univ, Dept Epidemiol, Rotterdam, Netherlands
[5] Erasmus Univ, Dept Biostat, Rotterdam, Netherlands
[6] Leiden Univ, Med Ctr, Dept Gastroenterol, NL-2300 RA Leiden, Netherlands
关键词
D O I
10.1046/j.1365-2036.2000.00806.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. Aim: To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both drugs following administration on day 1 and day 6. Methods: Randomized, two-way crossover study, Sixteen Helicobacter pylori-negative healthy subjects, whose gastric acidity fell below pH 4 for 70% of a 24-h baseline period were included, Intragastric pH was measured continuously, Results: On day 1 both drugs significantly raised median 24-h gastric pH compared to baseline. Median pH and percentages of time above pH 3 and 4 on day 1 and day 6 of administration were not significantly different, with the exception of median daytime pH on day 6, which was significantly higher with omeprazole (4.65 vs. 4.05), AUC and C-max of omeprazole were significantly increased on day 6. AUC and C-max of pantoprazole were not significantly increased. Conclusions: No significant difference in acid-inhibitory effect on day 1, On day 6 median daytime pH was significantly higher with omeprazole MUPS, but the percentages of time spent above pH 3 and 4 were not significantly different. The significant increase in bioavailability of omeprazole may contribute to the increased effect on day 6.
引用
收藏
页码:1057 / 1064
页数:8
相关论文
共 21 条
[11]   SIMILARITIES AND DIFFERENCES IN THE PROPERTIES OF SUBSTITUTED BENZIMIDAZOLES - A COMPARISON BETWEEN PANTOPRAZOLE AND RELATED-COMPOUNDS [J].
KROMER, W .
DIGESTION, 1995, 56 (06) :443-454
[12]   DETERMINATION OF OMEPRAZOLE AND METABOLITES IN PLASMA AND URINE BY LIQUID-CHROMATOGRAPHY [J].
LAGERSTROM, PO ;
PERSSON, BA .
JOURNAL OF CHROMATOGRAPHY, 1984, 309 (02) :347-356
[13]   THE MECHANISM OF ACTION OF THE GASTRIC-ACID SECRETION INHIBITOR OMEPRAZOLE [J].
LINDBERG, P ;
NORDBERG, P ;
ALMINGER, T ;
BRANDSTROM, A ;
WALLMARK, B .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (08) :1327-1329
[14]   HUMAN POSTPRANDIAL GASTRIC-EMPTYING OF 1-3-MILLIMETER SPHERES [J].
MEYER, JH ;
ELASHOFF, J ;
PORTERFINK, V ;
DRESSMAN, J ;
AMIDON, GL .
GASTROENTEROLOGY, 1988, 94 (06) :1315-1325
[15]  
MEYER JH, 1991, PANCREATIC ENZYMES H, P71
[16]   Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs [J].
Meyer, UA .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 :S21-S25
[17]  
MOSSNER J, 1995, ALIMENT PHARM THERAP, V9, P321
[18]  
MULDER CJJ, 1999, GUT, V45, pA39
[19]  
REHNER M, 1995, ALIMENT PHARM THERAP, V9, P411
[20]  
SHIN JM, 1994, ALIMENT PHARM THER, V8, P11